Hebei Yanda Ludaopei Hospital
33
1
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
3.0%
1 terminated/withdrawn out of 33 trials
90.9%
+4.4% vs industry average
3%
1 trials in Phase 3/4
10%
1 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (33)
Blood mNGS for Diagnosing Invasive Pulmonary Fungal Disease in Hematologic Patients
Role: collaborator
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy
Role: collaborator
Second Haplo-transplantation for Graft Failure
Role: collaborator
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Role: lead
CMV-TCR-T Cells for CM Virus Infection After HSCT
Role: lead
Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Role: collaborator
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
Role: collaborator
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
Role: collaborator
Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients
Role: lead
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)
Role: lead
A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Role: lead
EBV-TCR-T Cells for EB Virus Infection After HSCT
Role: lead
CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients
Role: lead
CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients
Role: lead
Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia
Role: collaborator
CD19-CAR-T in B-cell Malignancies Patients
Role: lead
CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients
Role: lead
mNGS Versus Blood Culture in FN
Role: collaborator
Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Role: collaborator
Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia
Role: collaborator